National Cancer Research Network, Blood Cancer
Conditions
Interventions
Patients will be randomised to a single unit from either a low or high responding donor. The responsiveness of the donor's platelets in vitro to agonists ( molecules which "switch on" platelets) has b
Sponsors
NHS Blood and Transplant [NHSBT] (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 16 years or older 2. Stable Haematology/Oncology Patients at Addenbrooke?s Hospital 3. Thrombocytopenia secondary to bone marrow failure, requiring platelet transfusions according to local and British Committee for Standards in Haematology (BCSH) Guidelines 4. Patients who, if peripheral venous access for blood sampling is required, have adequate access and will consent to their blood being taken in this way 5. Patients able to give written informed consent 6. Male or female
Exclusion criteria
Exclusion criteria: 1. Inherited or acquired clotting disorders 2. Inherited or acquired platelet function disorders 3. Current Acute Promyelocytic Leukaemia 4. Previously documented WHO Grade 4 bleeding (debilitating blood loss) 5. Palpable Splenomegaly 6. Immunological refractoriness to platelet transfusion 7. Require HLA or HPA matched platelets 8. Pregnant or lactating women 9. Other active malignancy in past 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Count increment at 1 hour; measured as difference between pre and 1 hour post transfusion count. Corrected for dose and BSA. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. 24 hour count increment measured as difference between pre and 24 hour count 2. Bleeding Score - both patient and clinician assessed 3. Red cell transfusion measured as number of red cell units transfused 4. Time to next platelet transfusion measured as number of days to next transfusion | — |
Countries
United Kingdom
Outcome results
None listed